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Background
Natural killer (NK) cells are important key players of the
innate immune system and provide immediate defense
against viral infection and tumor transformation. There-
fore, their potential in cancer immunotherapy has grown
prominently in the last years [1]. As is known from the lit-
erature, the Signal Transducer and Activator of Transcrip-
tion 1 (STAT1) plays an important role for NK cell
function, since STAT1-deficient mice display impaired
basal NK cytolytic activity in vitro and are unable to reject
transplanted tumors in vivo [2]. STAT1 mediates signals
downstream of interferons and gets activated by phospho-
rylation of several tyrosine and serine residues. In particu-
lar phosphorylation of S727 is considered a prerequisite
for the full-fledged activation of STAT1 [3]. The aim of this
project is to investigate the role of STAT1-S727 in NK cell-
mediated cytotoxicity and tumor surveillance.
Methods
The analysis of STAT1-/-, STAT1-S727A and wild-type mice
includes the preparation of primary splenic NK cells and
their investigation regarding proliferation ([3H]thymi-
dine-incorporation), cytotoxicity (standard [51Cr]-
release) and cytokine production (ELISA, multi-plex bead
arrays). In vivo tumor models are employed using NK-sen-
sitive tumor cell lines (v-abl+ leukemia, B16 melanoma,
4T1 breast cancer).
Results
Wild-type NK cells from untreated healthy mice display
basal phosphorylation on STAT1-S727 in vivo. Surpris-
ingly, disruption of this phosphorylation site by mutating
serine727 to alanine (STAT1-S727A) significantly
enhances NK cell cytotoxicity towards various target cells
in vitro compared to wild-type. Moreover, we demonstrate
that STAT1-S727A mice do not only display delayed
leukemia onset but also lower susceptibility to intrave-
nously administered B16 (melanoma) and 4T1 (metasta-
sizing breast cancer) cells compared to STAT1-/- and wild-
type mice.
Conclusion
Obviating the phosphorylation of STAT1-S727 seems to
increase NK cell cytotoxicity in vitro and in vivo. As an ulti-
mate goal we aim to find the underlying mechanism(s)
and upstream regulator(s), since loosening the brake on
NK cell functions could represent a potential novel strat-
egy in cancer therapy.
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